Central retinal vein occlusion
diseaseOn this page
Also known as central retinal vein retinal vein occlusioncentral retinal Venous occlusionretinal vein occlusion of central retinal vein
Summary
Central retinal vein occlusion (MONDO:0002303) is a disease and 52 clinical trials. Top therapeutic interventions include bevacizumab, aflibercept, and ranibizumab. A subtype of vein disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 16
- Clinical trials: 52
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 28 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
16 HPO clinical features (Orphanet curated; top 16 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0011505 | Cystoid macular edema | Very frequent (80-99%) |
| HP:0030497 | Macular cotton wool spot | Very frequent (80-99%) |
| HP:0031805 | Intraretinal hemorrhage | Very frequent (80-99%) |
| HP:0000572 | Visual loss | Frequent (30-79%) |
| HP:0001085 | Papilledema | Frequent (30-79%) |
| HP:0012841 | Retinal vascular tortuosity | Frequent (30-79%) |
| HP:0040049 | Macular edema | Frequent (30-79%) |
| HP:0000501 | Glaucoma | Occasional (5-29%) |
| HP:0000580 | Pigmentary retinopathy | Occasional (5-29%) |
| HP:0000608 | Macular degeneration | Occasional (5-29%) |
| HP:0000622 | Blurred vision | Occasional (5-29%) |
| HP:0001129 | Large central visual field defect | Occasional (5-29%) |
| HP:0004328 | Abnormal anterior eye segment morphology | Occasional (5-29%) |
| HP:0007984 | Electronegative electroretinogram | Occasional (5-29%) |
| HP:0030666 | Retinal neovascularization | Occasional (5-29%) |
| HP:0100014 | Epiretinal membrane | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | central retinal vein occlusion |
| Mondo ID | MONDO:0002303 |
| Orphanet | 411527 |
| DOID | DOID:2450 |
| ICD-10-CM | H34.81 |
| ICD-11 | 1146548497 |
| NCIT | C118859 |
| SNOMED CT | 68478007 |
| UMLS | C0154841 |
| MedGen | 509679 |
| GARD | 0021734 |
| Anatomy (UBERON) | UBERON:0001673 |
| Is cancer (heuristic) | no |
Also known as: central retinal vein retinal vein occlusion · central retinal Venous occlusion · retinal vein occlusion of central retinal vein
Disease family
This is a subtype of vein disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vein disorder › central retinal vein occlusion
Related subtypes (12): venous insufficiency, portal vein thrombosis, occlusion of tributary of retinal vein, cavernous sinus meningioma, superior vena cava angiosarcoma, pulmonary vein leiomyosarcoma, phlebitis, malignant jugulotympanic paraganglioma, varicose disease, vein of Galen aneurysm, isolated splenic vein thrombosis, isolated mesenteric vein thrombosis
Subtypes (1): central retinal vein occlusion with macular edema
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 52.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 18 |
| PHASE3 | 10 |
| PHASE1 | 8 |
| PHASE4 | 7 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07240649 | PHASE4 | NOT_YET_RECRUITING | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications |
| NCT00566761 | PHASE4 | TERMINATED | Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO |
| NCT01448018 | PHASE4 | COMPLETED | Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion |
| NCT01827722 | PHASE4 | UNKNOWN | Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion |
| NCT02274259 | PHASE4 | COMPLETED | Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen |
| NCT02503540 | PHASE4 | COMPLETED | Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO |
| NCT02800642 | PHASE4 | COMPLETED | Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO |
| NCT00500045 | PHASE2/PHASE3 | TERMINATED | Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions |
| NCT00517257 | PHASE3 | UNKNOWN | Atorvastatin for the Treatment of Retinal Vein Occlusion |
| NCT00532142 | PHASE2/PHASE3 | COMPLETED | The ROVO Study: Radial Optic Neurotomy for CVO |
| NCT00567697 | PHASE3 | COMPLETED | A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO |
| NCT00906685 | PHASE3 | COMPLETED | Bevacizumab for Central Retinal Vein Occlusion Study |
| NCT01396083 | PHASE3 | COMPLETED | Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) |
| NCT01535261 | PHASE3 | COMPLETED | Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion |
| NCT01969708 | PHASE3 | COMPLETED | Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) |
| NCT01976312 | PHASE3 | COMPLETED | Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) |
| NCT03223714 | PHASE3 | COMPLETED | Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion |
| NCT03810313 | PHASE3 | TERMINATED | Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion |
| NCT04740931 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
| NCT00211471 | PHASE2 | TERMINATED | Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). |
| NCT01178697 | PHASE2 | UNKNOWN | Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) |
| NCT01471691 | PHASE1/PHASE2 | COMPLETED | Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab |
| NCT01724554 | PHASE1/PHASE2 | COMPLETED | Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion |
| NCT02405741 | PHASE2 | UNKNOWN | Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients |
| NCT03981549 | PHASE1/PHASE2 | COMPLETED | Treatment of Central Retinal Vein Occlusion Using Stem Cells Study |
| NCT04667910 | PHASE2 | COMPLETED | 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) |
| NCT00406796 | PHASE1 | COMPLETED | Lucentis for Central Retinal Vein Occlusion (CRVO) |
| NCT00969293 | PHASE1 | TERMINATED | Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion |
| NCT01011374 | PHASE1 | UNKNOWN | Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion |
| NCT01028248 | PHASE1 | COMPLETED | Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion |
| NCT01581411 | PHASE1 | COMPLETED | Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion |
| NCT02173873 | PHASE1 | UNKNOWN | Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I |
| NCT02747030 | PHASE1 | COMPLETED | Phase I RVC With Ocriplasmin for CRVO |
| NCT03417401 | PHASE1 | WITHDRAWN | Surgical Stabilizer Assisted RVC With rtPA for CRVO |
| NCT05476926 | Not specified | ACTIVE_NOT_RECRUITING | A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products |
| NCT00383773 | Not specified | UNKNOWN | Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion |
| NCT00556114 | Not specified | COMPLETED | A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging |
| NCT00952614 | Not specified | COMPLETED | A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion |
| NCT01231633 | Not specified | COMPLETED | Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) |
| NCT01303276 | Not specified | UNKNOWN | Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 5 |
| AFLIBERCEPT | 4 | 3 |
| RANIBIZUMAB | 4 | 3 |
| FARICIMAB | 4 | 2 |
| TRIAMCINOLONE | 4 | 2 |
| BROLUCIZUMAB | 4 | 1 |
| DEXAMETHASONE | 4 | 1 |
| LIDOCAINE | 4 | 1 |
| NIACIN | 4 | 1 |
| OXYGEN | 4 | 1 |
| PROPARACAINE | 4 | 1 |
| ANECORTAVE ACETATE | 3 | 1 |
| CHEMBL4781942 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |